BR
BRSYF.US BrainsWay Ltd
- Market cap
- USD 427M
- P/E
- 44.3x
- P/B
- 5.20x
- ROE
- 11.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is BRSYF.US undervalued?
Graham numberThe Graham number of BrainsWay Ltd cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
BrainsWay Ltd fundamental analysis
No fundamental analysis for BrainsWay Ltd yet.
BrainsWay Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About BrainsWay Ltd
BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious and late-life depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post-traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, po…
Full company profileBrainsWay Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
BrainsWay Ltd annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 11.5M | 11.1M | 16.4M | 23.1M | 22.1M | 29.7M | 27.2M | 31.8M | 41.0M | 56.5M | 67.1M |
| Gross Profit | 9.10M | 8.55M | 12.8M | 18.0M | 17.0M | 23.1M | 20.0M | 23.5M | 30.6M | 42.6M | 51.0M |
| Operating Income | -2.07M | -6.61M | -5.11M | -8.48M | -4.83M | -5.00M | -12.7M | -4.96M | 1.39M | 4.68M | 9.23M |
| EBITDA | -1.42M | -5.73M | -4.42M | -6.81M | -2.15M | -4.84M | -10.8M | -2.37M | 5.53M | 6.22M | 12.0M |
| Net Income | -2.40M | -7.05M | -6.48M | -10.3M | -5.39M | -6.46M | -13.3M | -4.20M | 2.92M | 8.26M | 9.55M |
| EPS | -0.17 | -0.48 | -0.39 | -0.50 | -0.24 | -0.21 | -0.40 | -0.13 | 0.08 | 0.19 | 0.21 |
| Balance Sheet | |||||||||||
| Total Assets | 20.0M | 27.0M | 23.6M | 38.7M | 34.0M | 75.7M | 64.5M | 63.0M | 94.3M | 113M | 126M |
| Total Liabilities | 9.68M | 14.3M | 16.7M | 14.5M | 14.4M | 18.4M | 19.1M | 21.4M | 32.0M | 34.7M | 40.1M |
| Shareholders' Equity | 10.3M | 12.7M | 6.95M | 24.2M | 19.6M | 57.3M | 45.4M | 41.6M | 62.3M | 73.2M | 82.2M |
| Cash & Short-term Investments | 9.17M | 14.5M | 8.97M | 21.9M | 17.2M | 57.3M | 47.9M | 46.0M | 69.3M | 69.1M | 63.4M |
| Total Debt | 810K | 2.73M | 2.83M | 414K | 429K | 754K | 488K | 471K | 5.62M | 6.82M | 6.87M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -2.40M | -3.47M | -3.77M | -7.24M | -1.44M | 884K | -9.76M | 1.28M | 10.3M | 18.9M | 18.2M |
| Capital Expenditure | 408K | 985K | 1.97M | 3.31M | 2.47M | 2.24M | 20.1K | 2.39M | 3.79M | 1.89M | 2.70M |
| Free Cash Flow | -2.81M | -4.45M | -5.75M | -10.6M | -3.91M | -1.35M | -9.78M | -1.10M | 6.50M | 17.6M | 16.5M |
| Ratios | |||||||||||
| ROE | -23.3% | -55.5% | -93.2% | -42.6% | -27.4% | -11.3% | -29.4% | -10.1% | 4.7% | 11.3% | 11.6% |
| ROA | -12.0% | -26.1% | -27.5% | -26.7% | -15.8% | -8.5% | -20.7% | -6.7% | 3.1% | 7.3% | 7.6% |
| Net Profit Margin | -20.8% | -63.3% | -39.5% | -44.7% | -24.4% | -21.8% | -49.1% | -13.2% | 7.1% | 14.6% | 14.2% |
| Debt to Equity | 0.08x | 0.21x | 0.41x | 0.02x | 0.02x | 0.01x | 0.01x | 0.01x | 0.09x | 0.09x | 0.08x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
BrainsWay Ltd dividends
BrainsWay Ltd has not paid dividends in the last 9 fiscal years.
Last stock split: 1:4 on May 23, 2011.
Who owns BrainsWay Ltd
- Insiders 9.49%
- Institutions 10.42%
- Public & others 80.09%
- Shares outstanding 40.3M
- Free float 24.1M
BrainsWay Ltd company profile
- Company name
- BrainsWay Ltd
- Ticker
- BRSYF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 129
- Fiscal year end
- December
- Address
- 16 Hartum St, Jerusalem, Israel, 9777516
- Phone
- 972 2 582 4030
- Website
- brainsway.com
About BrainsWay Ltd
BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious and late-life depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post-traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company serves doctors, hospitals, and medical centers in the field of psychiatry. The company was founded in 2003 and is headquartered in Jerusalem, Israel.
BrainsWay Ltd management
10- Mr. Hadar LevyChief Executive Officer · born 1973
- Dr. David Zacut M.D.Co-Founder & Vice-Chairman · born 1953
- Prof. Abraham Zangen Ph.D.Co-Founder, Member of Scientific Advisory Board & Director · born 1970
- Mr. Ido MaromChief Financial Officer · born 1976
- Mr. Gilead Moiseyev Ph.D.Chief Technology Officer · born 1972
- Dr. Colleen Hanlon Ph.D.Vice President of Medical Affairs · born 1980
- Mr. Michael CohenVice President of US Sales
- Dr. Yiftach Roth Ph.D.Founder & Chief Scientific Officer · born 1971
- Mr. Dor HagaiVice President of Operations
- Mr. Menachem C. Klein Esq.VP, General Counsel & Corporate Secretary